Editing Ranbaxy Laboratories (section)

===Trading===
For the twelve months ending on 31 December 2005, the company's global sales were US$1,178 million, with overseas markets accounting for 75% of global sales (USA: 28%, Europe: 17%, Brazil, Russia, and China: 29%).{{citation needed|date=August 2018}}

In December 2005, Ranbaxy's share price was hit by a patent ruling disallowing production of its own version of [[Pfizer]]'s [[cholesterol]]-cutting drug [[Lipitor]], which had annual sales of more than $10 billion.<ref>[http://news.bbc.co.uk/2/hi/business/4542358.stm Patent ruling hits Ranbaxy shares]. BBC News (19 December 2005).</ref> 

In June 2008, Ranbaxy settled the patent dispute with Pfizer, allowing them to sell [[atorvastatin calcium]], the [[generic version]] of Lipitor and atorvastatin calcium-amlodipine besylate, the generic version of Pfizer's [[Caduet]], in the US, starting on 30 November 2011.{{Citation needed|date=May 2009}}

On 23 June 2006, the US [[Food & Drug Administration]] granted Ranbaxy a 180-day exclusivity period to sell [[simvastatin]] ([[Zocor]]) in the US as a [[generic drug]] at 80&nbsp;mg strength. Ranbaxy competed with the maker of brand-name Zocor, [[Merck & Co.]]; IVAX Corporation (which was acquired by and merged into Teva Pharmaceutical Industries Ltd.), which has 180-day exclusivity at strengths other than 80&nbsp; mg; and [[Dr. Reddy's Laboratories]] and India, whose authorized generic version (licensed by Merck) is exempt from exclusivity.{{citation needed|date=January 2016}}

On 1 December 2011, Ranbaxy got approval from the FDA to launch the generic version of Lipitor in the United States after the drug's patent expired.<ref>{{Cite web |url=https://www.bloomberg.com/businessweek/news/2011-11-30/ranbaxy-s-lipitor-copy-approved-by-fda-threatening-pfizer-sales.html | title = Ranbaxys lipitor copy approved by fda threatening pfizer sales |website=[[Bloomberg News]] |access-date=5 October 2020 }}</ref><ref>{{cite news| url=http://timesofindia.indiatimes.com/business/india-business/Ranbaxy-gets-approval-to-launch-generic-Lipitor-in-US/articleshow/10940626.cms | work=The Times of India | title=Ranbaxy gets approval to launch generic Lipitor in US – The Times of India}}</ref>